A Stage 1, Prospective, Randomized, Placebo-Controlled, Double- Blind Study to Evaluate the Safety and Efficacy of Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Subjects With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

A Stage 1, Prospective, Randomized, Placebo-Controlled, Double- Blind Study to Evaluate the Safety and Efficacy of Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Subjects With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Alpha 1-antitrypsin deficiency
  • Focus Therapeutic Use
  • Sponsors Baxalta; Shire
  • Most Recent Events

    • 24 Oct 2017 Planned End Date changed from 1 Jul 2021 to 30 Jul 2021.
    • 24 Oct 2017 Planned primary completion date changed from 1 Jul 2021 to 30 Jul 2021.
    • 22 Apr 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top